

Date: June 23, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra € Mumbai – 400 051 Symbol: ONESOURCE
---	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

Ref: Appointment of Director

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors has approved the appointment of Mr. Colin Michael Bond (DIN: 10982819), as an Additional director (Non-Executive, Independent), of the Company, with effect from June 23, 2025, subject to the approval of the shareholders.

The details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure I.

Kindly take the above information on your record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Annexure “I”

Sr. No	Particulars	Details of the Director
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Colin Michael Bond (DIN: 10982819), as an Additional Director of the Company under the category of Non-Executive Independent Director.
2.	Date of appointment and terms of appointment	Effective June 23, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders’ approval.
3.	Brief Profile	<p>A global finance executive, Mr. Colin Michael Bond has served as Chief Financial Officer for three publicly listed companies over a span of 15 years, across the Swiss, German, and U.S. markets. In addition to his CFO roles, he has completed full-term tenures as a Board Member and Audit Committee Chairman for listed companies in Switzerland, United Kingdom and Germany.</p> <p>His career is distinguished by a strong track record of high-impact transactions, including two IPOs, a corporate spin-off, a sale to private equity, an acquisition followed by delisting, a sale and subsequent delisting, multiple public bond issuances and several material M&A activities.</p> <p>Mr. Colin Michael Bond has deep experience in strategic and operational areas. These include leadership of Audit and Risk Committees, corporate finance and corporate governance, as well as deep expertise in strategy development and execution, mergers and acquisitions (M&A), and operational efficiency.</p> <p>He has successfully led large-scale business transformation initiatives, digitalization and IT integration and ESG initiatives—aligning business performance with long-term stakeholder interests.</p> <p>He earned his MBA from London Business School (1993–1996). Mr. Colin Michael Bond is a Fellow of the Institute of Chartered Accountants in England and Wales, underlining his expertise in financial management and compliance. Earlier, he became a Member of the Royal Pharmaceutical Society of Great Britain in 1985 after completing his BSc in Pharmacy with Upper Second Class Honours from the University of Aston in Birmingham in 1984.</p>

4.	Disclosure of relationships between directors (in case of appointment of a director)	None
5.	Disclosure as per NSE/CML/2018/24 dated June 20, 2018 and BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018.	Mr. Colin Michael Bond is not debarred from holding the office of Director by any SEBI order or any other statutory authority.

